|
Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in lung cancer patients receiving carboplatin-based therapies. |
| |
|
No Relationships to Disclose |
| |
|
Consulting or Advisory Role - Helsinn Healthcare; Merck; MSD; Tesaro |
| |
|
|
Stock and Other Ownership Interests - Merck |
| |
|
No Relationships to Disclose |
| |
Elizabeth Beckford-Brathwaite |
|
Stock and Other Ownership Interests - Merck |
|
| |
|
|
Stock and Other Ownership Interests - Merck |
Travel, Accommodations, Expenses - Merck |
| |
|
|
| |
|
|
Stock and Other Ownership Interests - Takeda |
Travel, Accommodations, Expenses - Takeda |
| |
|
Honoraria - HERON; Merck; Tesaro |
Consulting or Advisory Role - HERON; Merck; Tesaro |
Speakers' Bureau - Merck; Tesaro |
Research Funding - Merck; Tesaro |
Travel, Accommodations, Expenses - Merck; Tesaro |